Iodide

Iodide

SCHEMBL19283626

C[N+]1(C)CCN(C(=O)C(Nc2nc3ccccc3[nH]2)c2cccc(C(F)(F)F)c2)CC1.[I-]

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGA5 P08648 1/20 0.46
▸ ITGB6 P18564 1/20 0.46
▸ ITGB8 P26012 1/20 0.46
▸ KLRK1 P26718 4/20 0.45
▸ MICA Q29983 4/20 0.45
▸ RAET1L Q5VY80 3/20 0.45
▸ MTOR P42345 1/20 0.43
▸ RAF1 P04049 1/20 0.41
▸ BRAF P15056 1/20 0.41
▸ PHGDH O43175 2/20 0.41
▸ LPAR2 Q9HBW0 1/20 0.38
▸ HRH4 Q9H3N8 1/20 0.38
▸ NTRK1 P04629 1/20 0.37
▸ NTRK2 Q16620 1/20 0.37
▸ TRPV1 Q8NER1 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ SCD O00767 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21821293 0.99 ITGA5 (0.46) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283810 0.91 KLRK1 (0.53) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283862 0.90 KLRK1 (0.52) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821288 0.90 KLRK1 (0.52) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821304 0.89 HRH4 (0.49) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821319 0.88 ITGA5 (0.49) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283725 0.88 ITGA5 (0.48) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283627 0.88 ITGA5 (0.46) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL21821297 0.88 TACR1 (0.48) ITGA5ITGB6ITGB8KLRK1MICA
SCHEMBL19283678 0.85 ITGA5 (0.44) ITGA5ITGB6ITGB8KLRK1MICA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11274092-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2022-03-15 — — US disclosed
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-06-24 — — US disclosed
EP-3419973-B1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-04-08 — — EP disclosed
EP-3419973-A1 NOVEL POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2019-01-02 — — EP disclosed
WO-2017144183-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2017-08-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210188804-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNJ2, KCNN2, KCNN1 ITGA5 3161/4885ITGB6 3120/4885ITGB8 3935/4885
US-11274092-B2 Potassium channel inhibitors KCNJ2, KCNJ11, KCNJ1 ITGA5 2293/4885ITGB6 2913/4885ITGB8 3978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback